# An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

> **NCT06179875** · PHASE3 · COMPLETED · sponsor: **Viridian Therapeutics, Inc.** · enrollment: 143 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** Veligrotug

## Key facts

- **NCT ID:** NCT06179875
- **Lead sponsor:** Viridian Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-31
- **Primary completion:** 2025-04-25
- **Final completion:** 2025-06-23
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06179875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06179875, "An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06179875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*